LOGIN  |  REGISTER
Cue Biopharma
Viking Therapeutics

Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences

November 25, 2025 | Last Trade: US$13.01 1.06 8.87

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December:

Citi Global Healthcare Conference (Miami)
Date:Tuesday, December 2, 2025
Time:1:00 pm ET
Format:Fireside Chat
Webcast:FTRE Citi webcast
 
Evercore 8th Annual Healthcare Conference (Miami)
Date:
Wednesday, December 3, 2025
Time:
10:50 am ET
Format:
Fireside Chat
Webcast:
FTRE Evercore webcast

The live webcasts and replay of the fireside chats will be accessible through the “Events” section of Fortrea’s  Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts:

Tracy Krumme (Investors) – 984-385-6707, This email address is being protected from spambots. You need JavaScript enabled to view it.
Sue Zaranek (Media) – 919-943-5422, This email address is being protected from spambots. You need JavaScript enabled to view it.
Kate Dillon (Media) – 646-818-9115, This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page